NCT04625556 Development of Urologic Registry for Personalized Medicine in Patients With Urologic Malignant Diseases by Analyzing Microbiome
| NCT ID | NCT04625556 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Yonsei University |
| Condition | Urological Malignancies |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,000 participants |
| Start Date | 2022-12-19 |
| Primary Completion | 2030-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,000 participants in total. It began in 2022-12-19 with a primary completion date of 2030-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Genitourinary malignancies such as prostate cancer, renal cell cancer, and bladder cancer in Korean population have been increased due to the aged population and the westernized lifestyles. With the advancement of technologies, studies have found that microbiome not only affects human physiological functions, such as metabolism, immunity, and haematopoiesis, but also plays a significant role in the development and progression of malignancies. However, the investigation of microbiome in urological malignances have been limited and few studies have been reported. Therefore, the investigator tried to evaluate the usefulness of microbiome in detection and monitoring of urological malignancies in Korean population. This study aims to use microbiome in tissue, plasma, stool and urine for the diagnosis, disease progression monitoring and therapeutic response evaluation. This study plan includes building big databases for microbiome of urological malignancies in Korean population.
Eligibility Criteria
Inclusion Criteria: * Patients diagnosed as urological malignancies (prostate cancer, renal cell cancer, bladder cancer, and ureter cancer) * Patients who have undergone surgeries due to urological malignancies in Severance Hospital, Sinchon from 2020.10 and 2030.10 * Those who agree to give permission to use their human source information * Those who agree with this study Exclusion Criteria: * Those who do not agree with this study * Vulnerable participants who are likely to be vulnerable to coercion or undue influence or lack decision-making
Contact & Investigator
Won Sik Ham
PRINCIPAL INVESTIGATOR
Severance Hospital
Frequently Asked Questions
Who can join the NCT04625556 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, studying Urological Malignancies. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04625556 currently recruiting?
Yes, NCT04625556 is actively recruiting participants. Contact the research team at uroham@yuhs.ac for enrollment information.
Where is the NCT04625556 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT04625556 clinical trial?
NCT04625556 is sponsored by Yonsei University. The principal investigator is Won Sik Ham at Severance Hospital. The trial plans to enroll 3,000 participants.